3
2
1

New Progress in China's BCI Technology! Paraplegic Patient Achieves "Brain-Controlled Water Drinking"

Release time:

2024-03-01

Recently, a team from Xuanwu Hospital Capital Medical University and School of Medicine, Tsinghua University used a BCI with implantable epidural electrodes to enable a quadriplegic patient to autonomously perform brain-controlled functions such as drinking water.

The patient had a complete spinal cord injury at the cervical vertebra due to a car accident, and had been in a state of quadriplegia for a long time. on October 24, 2023, the research team carried out the first clinical implantation trial of the wireless minimally invasive-implantable BCI for the patient, where neurosurgeons implanted two coin-sized BCI processors into the patient's skull, and the prosessors successfully capturing intracranial nerve signals from the sensorimotor encephalic region.


After three months of home rehabilitation training, the patient is now able to control the pneumatic gloves through brain electrical activity to autonomously perform brain-controlled functions such as drinking water. The patient's spinal cord injury clinical index and somatosensory evoked potential measurements have improved.

It is reported that the implantation of a second spinal cord injury patient was successfully completed at Beijing Tiantan Hospital on December 19, 2023.  The signal reception is normal, and the patient is currently receiving rehabilitation training at home.

Latest developments

【The YinFeng Life Continuation Project Debuts at the 2026 Annual Meeting of the Chinese Medical Association's Medical Ethics Branch—Ethics Leading Biotech Toward Benevolent Innovation】

The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.

Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross

Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.

Yinfeng Life Science Research Institute, in Collaboration with University of Science and Technology of China, Develops CryoSIM Platform, Published in Top Analytical Chemistry Journal Revolutionizing Oocyte Membrane Permeability Analysis Technology

The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.

Public Welfare Partnership: A Special Letter from the Jinan Red Cross

On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).

World’s First Achievement Highlights Brand Leadership

In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.

Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference

Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.